UF Innovate | The Hub resident company etectRx, Inc., a privately-held digital health company, announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV. The study, dubbed “MyTPill,” will assess patient adherence using two electronic adherence tracking technologies: the ID-Cap™ System from etectRx and an electronic pillbox. The study will provide insight into how digital pill systems can help patients who have significant health risks due to nonadherence.
The MyTPill Study, which marks etectRx’s third NIH-sponsored study at Brigham and Women’s Hospital within the last two years, kicked off in March and will include 80 patients over the next four years. Patients will track their use of HIV medication by using the ID-Cap System for three months and an electronic pillbox for three months, with a short break in between. The research sites include leaders in HIV care at Fenway Health in Boston and at the University of Miami/Jackson Memorial HIV Clinic in Miami.Learn more about etectRx Announces Launch of MyTPill Study To Address Medication Adherence Among HIV+ Prescription Opioid Users.